NCT01760811View on ClinicalTrials.gov

CETUXIMAB Given for 3 Weeks as Neoadjuvant Treatment in Locally Advanced Tongue Cancer ; A NEW PARADIGM OF TREATMENT

PHASE1/PHASE2UnknownINTERVENTIONAL
Enrollment

25

Participants

Timeline

Start Date

January 31, 2013

Primary Completion Date

December 31, 2015

Study Completion Date

December 31, 2017

Conditions
Squamous Cell Carcinoma
Interventions
DRUG

Erbitux,merck serono

cetuximab loading dosage 400mg/m2 followed by weekly 250mg/m2 2 weeks

Trial Locations (1)

49100

Rabin Medical Center, Petah Tikva

Sponsors
All Listed Sponsors
collaborator

Kaplan Medical Center

OTHER

collaborator

Meir Medical Center

OTHER

lead

Rabin Medical Center

OTHER